You are here
CHANTEST, INC.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car
Amount: $1,184,308.00DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre- clinical cardiac safety testing. We have characterized a ...
SBIRPhase II2012Department of Health and Human Services National Institutes of Health -
Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car
Amount: $149,275.00DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre-clinical cardiac safety screening. We have recently charac ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
Development of a Complete Proarrhythmic Safety Profile for Drugs
Amount: $149,322.00DESCRIPTION (provided by applicant): ChanTest's goal is to commercialize a comprehensive non-clinical proarrhythmic profile that will screen compounds through a battery of models that span from the mo ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
New drugs for treatment of atrial fibrillation
Amount: $0.00DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
New drugs for treatment of atrial fibrillation
Amount: $580,448.00DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present ...
SBIRPhase II2003Department of Health and Human Services National Institutes of Health -
New drugs for treatment of atrial fibrillation
Amount: $99,924.00Atrial fibrillation (AF) is the commonest cardiac arrhythmia and in its chronic form affects more than two million patients in the USA. AF is associated with cardiac and non-cardiac diseases. About 10 ...
SBIRPhase I2001Department of Health and Human Services National Institutes of Health -
NOVEL SIMPLE SCREEN FOR POTASSIUM CHANNELS
Amount: $89,263.00N/A
SBIRPhase I1998Department of Health and Human Services